23:10:37 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Neodynamics är verksamma inom medicinteknik. Idag är verksamheten inriktad mot att utveckla och kommersialisera produkter för behandling av kritiska sjukdomar. Via egenutvecklad mikropulsteknologi erbjuder bolaget precisionsbehandlingar mot bland annat cancer. Lösningarna används främst vid bröstcancer hos kvinnor. Huvudkontoret ligger i Lidingö.

Kalender

2023-02-17 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning NEOD 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-12 Kvartalsrapport 2022-Q1
2022-02-25 Extra Bolagsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning NEOD 0.00 SEK
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-26 Årsstämma 2021
2021-02-17 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-11-19 Extra Bolagsstämma 2020
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-29 Ordinarie utdelning NEOD 0.00 SEK
2020-05-28 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-05 Bokslutskommuniké 2019
2020-01-28 Extra Bolagsstämma 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning NEOD 0.00 SEK
2019-05-23 Årsstämma 2019
2019-05-21 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018
2022-04-28 12:00:00

NeoDynamics AB (publ) (NeoDynamics or "the Company") received a conditional approval for admission to trading of the Company's shares on the Nasdaq First North Growth Market ("Nasdaq First North") on April 12, 2022. For this reason, the company has published a Supplementary document on its website in accordance with Nasdaq First North Growth Markets' listing requirements.

The Supplementary document can be found on the Company's website:

SV: https://www.neodynamics.com/sv-se/aktien

EN: https://www.neodynamics.com/en-gb/shares

DE: https://www.neodynamics.com/de-de/aktien

The Prospectus published on March 4, 2022 and the  Supplementary Document constitutes the Company Description. The Supplementary document does not constitute a prospectus, has not been approved by the Swedish Financial Supervisory Authority and does not contain an offer to subscribe for the Company's shares or other financial instruments in Sweden or in any other jurisdiction.

For more information, please contact:
Anna Eriksrud, CEO

Phone: +46 708 444 966
Email: anna.eriksrud@neodynamics.com

About NeoDynamics
NeoDynamics AB (publ) is a Swedish medical technology company that works to improve the diagnosis and treatment of cancer. The company's first product NeoNavia®, which is a new pulse biopsy system for ultrasound-guided tissue sampling, is now being introduced to the market. The biopsy system is based on a patented pulse technology based on research at Karolinska Institutet in Sweden. NeoNavia® is being evaluated for the diagnosis of breast cancer at leading clinics in the UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in the breasts and lymph nodes of over 500 patients.

About NeoNavia

NeoNavia is a modern biopsy system with a completely new patented pulse technology that is intended to be used for ultrasound-guided tissue sampling. It consists of a base unit, a handset and three types of biopsy needles. Each needle type is driven by the new pulse technology that provides a more controlled needle insertion and precise placement of the needle in the tumor while enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer doctors and patients a precise and reliable tissue sampling that enables a correct diagnosis and individualized treatment.